Dawn Eichenfield, MD, PhD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Arcutis
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Chiesi
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Apogee
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Beiersdorf
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Eli Lilly and Company
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Eli Lilly and Company
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Galderma
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Galderma
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Incyte
    Date added:
    10/20/2026
    Date updated:
    10/20/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Incyte
    Date added:
    10/20/2026
    Date updated:
    10/20/2026

Pages

Return to FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS COMPLEX Recognition, Treatment and Case-Based Management